Averroes: Journal for Science and Religious Studies

Vol. 3 No. 1 2026
DOI: 10.62446

Clinical Decision Support Systems for Dementia Management Using Predictive Analytics and Explainable AI

Moses Adeolu Agoi[1], Gbenga Oyewole Ogunsanwo[2], Bamidele Olumuyiwa Alaba[3], Asep Suraya Maulana[4]

Affiliasi: [1]Lagos State University of Education, Lagos Nigeria, [2]Tai Solarin University of Education, Ogun Nigeria, [3]Tai Solarin University of Education, Ogun Nigeria, [4]Universitas Islam Negeri K.H Abdurrahman Wahid Pekalongan.

Corresponding Author:

Email: agoi4moses@gmail.com

Abstract

Research Background: *Dementia is a growing global public health challenge driven by population ageing and increased life expectancy. Clinical Decision Support Systems (CDSS) have emerged as important tools to assist clinicians in early diagnosis, risk stratification, prognosis estimation, and personalized care planning in dementia management. Recent advances in predictive analytics and artificial intelligence (AI), particularly machine learning and deep learning models, have significantly enhanced the analytical capabilities of CDSS. However, the integration of these technologies into clinical practice remains limited due to concerns related to interpretability, generalizability, and ethical accountability. This study aims to review the development of CDSS for dementia management that integrate predictive analytics with Explainable Artificial Intelligence (XAI).*

Methods: *A systematic literature review was conducted using peer-reviewed publications from major academic databases published between 2017 and 2025. The analysis focuses on algorithmic approaches, data sources, validation strategies, and explainability techniques applied in contemporary dementia CDSS.*

Key Findings: *The findings indicate that predictive models demonstrate high accuracy in detecting early cognitive impairment and predicting disease progression. Nevertheless, their clinical implementation is often constrained by the "black-box" nature of many AI models and limited external validation. Explainable AI methods such as SHAP, LIME, and attention-based networks are increasingly used to improve transparency and clinician trust.*

Contribution: *This study contributes an integrative perspective that emphasizes the importance of balancing predictive performance with interpretability, ethical governance, and clinical usability.*

Conclusion: *It concludes that integrating predictive analytics with XAI is essential for developing trustworthy and clinically applicable CDSS in dementia care.*

Keyword : Clinical Decision Support Systems; Dementia Management; Explainable Artificial Intelligence; Predictive Analytics.

A. INTRODUCTION

Dementia is a group of progressive neurodegenerative disorders characterized by severe cognitive decline that disrupts daily functioning and independence, with Alzheimer's disease representing the most prevalent subtype globally (International 2023). The number of affected individuals continues to rise—currently exceeding 55 million worldwide and projected to triple by 2050—placing a substantial burden on healthcare systems (World Health Organization 2023), particularly in low- and middle-income countries. The clinical management of dementia is inherently complex, requiring longitudinal assessment, multimodal data integration, and personalized care planning. Conventional diagnostic approaches, including clinician observation, neuropsychological testing, neuroimaging, and biomarker evaluation, remain valuable but are time-consuming, resource-intensive, and subject to inter-rater variability. These challenges have accelerated the development of Clinical Decision Support Systems (CDSS) powered by predictive analytics and artificial intelligence (AI) to enhance diagnostic accuracy, consistency, and timeliness in clinical decision-making (Sutton dkk. 2020).

In practice, predictive analytics and machine learning algorithms—such as support vector machines, random forests, gradient boosting, and deep neural networks—have demonstrated high performance in identifying Mild Cognitive Impairment (MCI), predicting conversion to Alzheimer's disease, and optimizing treatment strategies using large-scale longitudinal datasets such as ADNI and UK Biobank. Several studies report classification accuracies exceeding 85% in distinguishing cognitively normal individuals from those with MCI or Alzheimer's disease (Jo, Nho, dan Saykin 2019). However, real-world clinical implementation remains limited due to concerns regarding model interpretability, data bias, and generalizability across heterogeneous patient populations. Furthermore, the absence of standardized evaluation frameworks, along with regulatory and ethical challenges related to transparency, accountability, informed consent, and algorithmic bias—particularly in underrepresented populations—has constrained the adoption of "black-box" AI models in safety-critical healthcare environments.

The literature indicates that the development of Clinical Decision Support Systems (CDSS) in dementia care has evolved from rule-based expert systems toward artificial intelligence (AI)–driven and data-adaptive approaches. Early CDSS relied on deterministic clinical rules, predefined neuropsychological thresholds, and expert heuristics, which ensured transparency but lacked flexibility in handling uncertainty and the heterogeneous manifestations of dementia (Clinical Decision Support (CDS) | Digital Healthcare Research t.t.). The emergence of machine learning (ML) introduced probabilistic reasoning and adaptive learning capabilities, enabling systems to detect complex patterns in high-dimensional clinical datasets. Supervised learning algorithms such as support vector machines (SVM), random forests (RF), and gradient boosting have demonstrated strong performance in classifying cognitive status and predicting disease progression, often outperforming traditional statistical models (Arbabshirani dkk. 2017). Neuroimaging-based ML models have achieved diagnostic accuracies exceeding 85–90% in distinguishing Alzheimer's disease from normal aging (Jo dkk. 2019). Deep learning architectures further enhanced CDSS capabilities by processing unstructured data such as MRI, PET, speech signals, and electronic health records, while recurrent neural networks (RNN) and long short-term memory (LSTM) models enabled longitudinal analysis of disease progression (Litjens et al., 2017). Longitudinal and multimodal modeling—integrating neuroimaging, genetic markers, clinical history, lifestyle factors, and digital biomarkers—has improved predictive accuracy and provided more comprehensive representations of dementia trajectories (Nguyen dkk. 2020). However, increasing model complexity has introduced interpretability challenges, as many ML systems operate as "black boxes," raising concerns about clinician trust, accountability, and ethical deployment (Holzinger dkk. 2019). Consequently, explainable AI (XAI) techniques such as SHAP and LIME have been adopted to provide feature-level explanations and enhance clinical transparency (Lundberg dan Lee 2017). Additionally, intrinsically interpretable models—including decision trees, generalized additive models (GAMs), and attention-based neural networks—seek to embed interpretability directly within model architecture (Choi dkk. 2016). Despite these advances, significant gaps remain in external validation, prospective clinical trials, and real-world implementation of CDSS (Sendak dkk. 2020). Ethical frameworks emphasizing transparency, accountability, fairness, and human oversight—such as the UNESCO Recommendation on the Ethics of Artificial Intelligence (UNESCO 2021)—highlight the necessity of explainability and responsible governance to ensure that AI-driven CDSS support, rather than replace, human clinical decision-making in dementia care.

Although existing research has primarily focused on improving algorithmic accuracy, a significant gap persists in integrating predictive performance with clinical interpretability, ethical accountability, and practical usability. This article addresses that gap by proposing an integrative approach that combines predictive analytics with Explainable Artificial Intelligence (XAI) in the development of CDSS for dementia care. Unlike prior studies that emphasize technical metrics alone, this paper foregrounds clinical relevance, model transparency, bias auditing, regulatory alignment, and support for shared decision-making (Tonekaboni dkk. 2019). By synthesizing these dimensions, the study contributes both conceptually and practically to the design of CDSS that are not only accurate but also trustworthy, ethically responsible, and ready for real-world clinical implementation.

This paper critically analyzes the use of CDSS in managing dementia that incorporate predictive analytics and explainable AI. The given study is the first to concentrate on clinical relevance, understandability, and the ethical application of the algorithm, unlike previous studies that are centered exclusively on algorithmic performance. The paper will inform the researchers, clinicians, and policymakers about the best practices and future perspectives of AI-enabled dementia care by synthesizing evidence on the current peer-reviewed literature and authoritative reports. This study adopts a systematic literature review approach to examine Clinical Decision Support Systems (CDSS) for dementia management that integrate predictive analytics and explainable artificial intelligence (XAI). To maintain the relevance and rigor of the methodology, the review also narrowed down on peer-reviewed and open-access scholarly articles published within the years 2017 to 2025. Search of literature was done in various academic databases and repositories such as PubMed, Scopus, Web of Science, IEEE Xplore, ScienceDirect, and Directory of Open Access Journals (DOAJ). Combined search terms included such key words as clinical decision support systems, dementia management, predictive analytics, machine learning, explainable AI, XAI, Alzheimer disease, and cognitive decline prediction. Search was refined with the help of the use of Boolean operators and truncation. Inclusion criteria Studies had to: (1) specifically deal with dementia or Alzheimer disease; (2) utilize predictive or machine learning models in the CDSS models; (3) include or assess explainability methods; and (4) present empirical results, system designs or test results. Research was not included when it concentrated on general AI methods but not specifically applied clinically, when not transparent in methodology, or it was not written in English. After the screening of abstracts and reviews of the full-text, thematic synthesis was applied to the selected studies in terms of predictive performance, explainability strategies, validation practices, ethical considerations, and clinical usability. The extraction of data was done in a standardized template such that the data would be consistent and comparable. The potential benefits of this methodology approach are that it allows the synthesis of the existing evidence in a structured way and it reveals the gaps in research that are pertinent to the clinical implementation of dementia CDSS.

B. DISCUSSION

1. Predictive Performance of CDSS in Dementia Management

The reviewed literature consistently shows that AI-driven Clinical Decision Support Systems (CDSS) for dementia detection and prognosis outperform many traditional statistical approaches, particularly in classification accuracy and prognostic capability. Supervised machine learning methods such as support vector machines (SVM), random forests, and neural networks have demonstrated strong performance in distinguishing cognitively normal (CN) individuals from those with mild cognitive impairment (MCI) or Alzheimer’s disease (AD). For example, convolutional neural network (CNN) models trained on neuroimaging datasets from repositories such as the Alzheimer's Disease Neuroimaging Initiative (ADNI) frequently achieve classification accuracies exceeding 90% for CN vs. AD tasks. One large study reported 90.10% accuracy for CN vs. AD classification, 87.46% for CN vs. progressive MCI, and 76.90% for stable vs. progressive MCI using a multimodal CNN approach on ADNI data (Mohsen 2025). In controlled experimental settings, optimized CNN architectures and transfer learning approaches have achieved classification accuracies as high as 98–99% (Bhandarkar dkk. 2024).

Deep learning architectures, including CNNs, hybrid CNN–LSTM models, and transformer-based networks, generally report the highest performance metrics. Jo, Nho, and Saykin (2019) summarize studies showing deep learning accuracy of up to 96% for AD classification, while prediction of conversion to MCI remains slightly lower but still clinically meaningful. These models are particularly effective at extracting high-dimensional spatial patterns from MRI and PET imaging, allowing them to detect subtle neuropathological changes that traditional statistical models—such as linear regression or survival models—may fail to capture. The integration of attention mechanisms and explainability tools such as Grad-CAM and SHAP further improves interpretability by linking model outputs with established disease biomarkers.

Despite these promising results, performance variability remains significant across datasets and clinical settings. Many high-accuracy results are derived from curated research cohorts like ADNI, which may not represent the heterogeneity of real-world populations. Models trained solely on ADNI often perform poorly on independent datasets such as AIBL or OASIS unless domain adaptation techniques are applied. Studies performing external validation report accuracies above 90% and AUC values greater than 0.96, though such validation remains relatively rare.

In addition to accuracy, modern models often report high precision, recall, and F1 scores exceeding 97%, with ROC-AUC values above 0.95. Traditional statistical models such as Cox regression remain useful for hypothesis testing and survival analysis but generally underperform with complex multimodal data. Overall, AI-based models show superior predictive performance, yet challenges related to data bias, limited external validation, and domain shift must be addressed to enable reliable real-world dementia CDSS deployment.



Figure. 1: *Chart illustrating the "diagnostic vs. prognostic trade-off" identified in the research work.*

Figure. 1 indicates that there is a performance gradient that is used to characterize the present condition of the dementia predictive analytics. AI models exhibit very high levels of maturity on the diagnostic front. These systems have successfully learnt how to identify known neuropathology with classification rates ranging between 90.10 percent and 99.00 percent between Cognitively Normal (CN) and Alzheimer's disease (AD). This strong performance can be explained by the fact that the models are able to pick high-dimensional spatial features in the case of a static neuroimaging data in which brain atrophy is already severe. On the other hand, when there is a prognostic task, a large performance gap can be observed. The accuracy decreases to 87.46 and 76.90 per cent when there is early prognosis and distinguishing between stable and progressive Mild Cognitive Impairment (MCI), respectively. Such a degradation is a characteristic of the so-called prognostic trade-off: the more the clinical task shifts away to detecting any current damage to forecasting future transition, the more the complexity goes exponentially. It takes longitudinal subtle biochemical changes that are much less noticeable than the obvious structural changes of a diagnosed AD brain to predict progression. Although AI achieves significantly higher accuracy in such tasks than traditional statistical algorithms (such as Cox regression), the 22.1% reduction in performance between optimized diagnosis and more complicated prognosis points to the current issue of clinical reliability in preclinical risk stratification.

2. Longitudinal Prediction and Disease Progression Modeling

Longitudinal modeling has become an important component of predictive Clinical Decision Support Systems (CDSS) in dementia research because it captures disease progression over time rather than relying on a single cross-sectional snapshot. Traditional classification tasks, such as distinguishing cognitively normal individuals from those with impairment, provide useful diagnostic information but cannot estimate individual rates of cognitive decline or determine when mild cognitive impairment (MCI) may progress to dementia. In contrast, longitudinal models—including recurrent neural networks (RNN), long short-term memory (LSTM) networks, and machine learning models combined with survival analysis—explicitly model temporal dependencies to predict future clinical states and time-to-conversion.

These approaches support proactive intervention by identifying individuals at high risk before neurodegeneration becomes irreversible. Studies show that deep RNN models trained on longitudinal cognitive and imaging data can effectively predict disease progression. For example, improved RNN architectures handling irregular follow-up times have achieved next-visit prediction accuracy above 90% (Wang, Qiu, dan Yu 2018). Machine learning integrated with survival analysis is also valuable for time-to-event prediction. Deep survival models such as DeepSurv have been applied to large cohorts ($n \approx 41,000$) with follow-up periods exceeding 12 years and have produced Harrell's concordance indices comparable to or better than classical survival methods such as Cox proportional hazards, DeepHit, and Kaplan–Meier. These results suggest that flexible deep survival models can capture complex nonlinear risk relationships better than traditional models assuming linear covariate effects.

Despite these advances, longitudinal CDSS face practical challenges. Clinical datasets often contain missing values, inconsistent follow-up schedules, and heterogeneous documentation across visits, which may reduce model robustness. Standard RNN models struggle with incomplete sequences unless advanced techniques such as imputation or model-based inference are applied. According to

Nguyen et al. (2020), irregular timing and incomplete data increase prediction uncertainty in temporal models. While basic imputation methods (e.g., mean substitution or last observation carried forward) may introduce bias, more advanced approaches—such as Bayesian estimation, time-attention mechanisms, or multi-task learning—can improve robustness by learning multiple clinical targets simultaneously and implicitly handling missing values.

Interpretability is another critical issue. Although attention mechanisms and survival modeling can highlight influential features or time windows, complex longitudinal inputs remain difficult to interpret clinically. Therefore, explainability-aware approaches combining attention mechanisms with visualization tools such as SHAP or temporal saliency maps are increasingly used to balance predictive performance with clinical usability. Explainability will play a vital role in the transformation of longitudinal CDSS between research prototypes and dependable clinical systems.



Figure. 2: *Visual plot illustrating how individual patient data points connect over time to reveal distinct trajectories of cognitive decline.*

Figure. 2 demonstrates a paradigm change in the stratification of risks of dementia: the transition to dynamism and trajectories in the past, not as snapshots. In classical cross-sectional analysis, one data point (such as a cognitive score of 24) could be used as a measure of a patient having Mild Cognitive Impairment (MCI), however, this does not predict their future. This ambiguity is addressed by the spaghetti plot that links individual data points in a 10-year follow-up scale. The analysis shows two unique trends. Stable MCI group of individuals (blue lines) exhibits a gradual, linear decrease that is frequently typical of aging. On the other hand, the group of the "Progressive MCI" (red lines) has a non-linear and faster downward slope. It is this crucial time-dependency that the Recurrent Neural Networks (RNNs) and the LSTM are intended to model. Artificial intelligence models can achieve prediction accuracy of next visit of cognitive loss (more than 90 percent) by not only analysing the current score but also the velocity and acceleration of the cognitive loss. More so, the visual also underscores the difficulty in data sparsity. The uneven distribution of points reflects the clinical reality of missed visits that are seen in real-life. This is overcome in advanced longitudinal CDSS that employ multi-task learning to impute the missing gaps to have a continuous risk estimation. This visual analysis concludes, at the end, that the clinical importance of watching how the health of a patient is going to evolve is much greater than the clinical importance of watching how it is at any one point in time.

3. Explainable AI and Clinical Interpretability

The use of explainable AI (XAI) methods has become essential for improving the clinical acceptability of dementia Clinical Decision Support Systems (CDSS) by making complex model predictions transparent and trustworthy for clinicians. Two widely used model-agnostic explanation methods are Shapley Additive exPlanations (SHAP) and Local Interpretable Model-agnostic Explanations (LIME), which quantify the contribution of individual features to predictive outcomes (Viswan Vimbi et al., 2024). A recent systematic review of their application in Alzheimer’s disease detection reported substantial improvements in interpretability through explicit feature ranking. Important predictors frequently identified include hippocampal volume, cognitive test scores such as MMSE, demographic variables, and genetic markers such as APOE ε4. In many studies, SHAP feature importance plots aligned with established clinical knowledge, with hippocampal atrophy and MMSE decline appearing among the most influential predictors in over 70% of the reviewed cases. This consistency increases clinicians’ confidence in AI-assisted recommendations.

For example, multimodal models combining clinical, neuroimaging, and genetic data have achieved high predictive accuracy while maintaining interpretability. A Random Forest model integrated with SHAP reached 98.83%

accuracy in multiclass Alzheimer prediction using OASIS-3 data, while also providing clear explanations for classification outcomes (Jahan et al., 2023). Such interpretability helps clinicians understand not only what the model predicts but also why the prediction is made, which is essential for clinical decision making, informed consent, and risk factor identification.

Models with built-in explainability further enhance usability. Attention-based neural networks generate attention weights or heatmaps that highlight important temporal or spatial patterns. The RETAIN model, for instance, achieved predictive performance comparable to standard RNNs while identifying influential time points and clinical variables in electronic health records (Choi dkk. 2016). More recent multimodal deep learning models with attention layers have reported strong performance (e.g., MAE $\approx$ 0.33; MSE $\approx$ 0.21) while quantifying the relative contribution of clinical and imaging data (S. Atypon et al., 2025).

Visualization methods such as Grad-CAM and saliency maps are also widely used in neuroimaging analysis to identify critical brain regions influencing predictions. These multilayered explanations improve clinician confidence by visually linking model outputs with clinically meaningful features. However, a practical trade-off remains between interpretability and predictive power. Simpler models such as logistic regression are more transparent but often less effective with high-dimensional multimodal dementia data, whereas deep learning models may achieve state-of-the-art performance (>95%) but require XAI techniques to interpret their outputs. Overall, integrating SHAP, LIME, and attention-based visualization substantially improves the interpretability and clinical reliability of dementia CDSS, helping clinicians understand, justify, and apply AI-assisted decisions in dementia diagnosis and treatment.

Figure. 3 represents the explainability of a complex AI model as a measure of the global and local effect of particular biomarkers to predict Alzheimer. Since the research established, the chart is efficient in breaking down black box decisions into an open-minded hierarchy of clinical drivers. Hippocampal Volume and MMSE scores are defined as the most influential ones at the top of the hierarchy, which is consistent with the commonly accepted neurological information according to which structural atrophy and cognitive deterioration are the main factors that determine the state of the disease.



Figure. 3: *Chart illustrating the "explainability" of a complex AI model.*

Directional distribution further explains the concept of the impact: the blue points (indicating low values) of hippocampal volume are depicted as having a considerable influence on the model output shifting to an AD diagnosis. This validates the fact that the model has acquired the direct correlation between brain volume and pathology. The fact that the system is able to visualize these attributions helps in addressing the barrier to clinical trust; clinicians are not simply shown an accuracy score such as the 98.8 percent reported in the OASIS-3 studies but are given a visual explanation as to why the classification is based on actionable, biological risk factors such as APOE-e4 status and the imaging markers.

4. Ethical Implications and Bias Considerations

Ethical analyses of artificial intelligence show that Clinical Decision Support Systems (CDSS) in dementia care raise complex concerns related to bias, fairness, and patient autonomy, which may compromise equity if not properly addressed. Studies on machine learning bias indicate that bias often arises from imbalanced or unrepresentative training data, flawed model design, and biases occurring throughout the development pipeline. These issues frequently disadvantage underrepresented populations such as ethnic minorities or individuals in low-resource settings (Mehrabi dkk. 2022). For instance, AI models trained primarily on clinical data from predominantly White and urban populations may show a decline in predictive accuracy of 10–15 percentage points when applied to other demographic groups. In dementia CDSS, such bias can intensify existing healthcare disparities by producing unreliable risk predictions for underrepresented patients.

Research on algorithmic fairness shows that differences in diagnostic performance across demographic groups are often overlooked without targeted subgroup analyses. Although explainability tools such as SHAP and LIME can reveal disproportionate feature influence—for example, age or socioeconomic status dominating risk scores—studies report inconsistent implementation of mitigation strategies. A meta-analysis of healthcare AI fairness found that fewer than 30% of reviewed models implemented specific bias-reduction methods such as re-sampling, re-weighting, or fairness constraints, indicating a gap between identifying and addressing bias.

Beyond algorithmic fairness, dementia CDSS also raise psychological and social concerns related to predictive labeling and risk communication. Predictive models can estimate the likelihood that mild cognitive impairment will progress to dementia long before symptoms appear in clinical records. Communicating such probabilistic risks can create anxiety, stigma, or ethical dilemmas, particularly when effective interventions are limited. Ethical evaluations of Alzheimer's prediction systems emphasize that risk disclosure may threaten patient autonomy if it imposes emotional burdens without clear clinical benefit. Consequently, sensitive counseling and shared decision-making are recommended.

Explainability supports ethical use by making algorithmic reasoning accessible to clinicians and patients, enabling informed consent and better understanding of prediction uncertainty. However, limited transparency may undermine patient trust and complicate consent procedures. Addressing fairness therefore requires proactive governance, including diverse datasets, stakeholder involvement, and institutional accountability. Techniques such as federated learning, careful dataset curation, and algorithmic auditing can help identify and reduce systemic bias. Overall, dementia CDSS should function as supportive tools that enhance—rather than replace—clinical judgment and patient-centered decision making.

5. Clinical Integration and Workflow Impact

Empirical research on real-world implementation shows that the effectiveness of AI-driven Clinical Decision Support Systems (CDSS) largely depends on how well they integrate into routine clinical workflows and respond to end-user needs. Implementation studies consistently find that CDSS embedded within electronic health record (EHR) systems are more likely to be adopted and sustained than standalone tools requiring clinicians to switch interfaces. Integrated features—such as contextual alerts, real-time risk scores, and automated notifications within clinician order entry systems—reduce workflow disruption and cognitive burden while encouraging meaningful clinical engagement. Evidence accumulated over decades demonstrates that CDSS embedded directly into clinical workflows are more likely to influence clinician behavior and improve care outcomes than disconnected systems (National Academy of Medicine, 2018).

Research on the sociotechnical aspects of implementation also emphasizes the importance of user-centered design, clinician training, and iterative feedback mechanisms. Sendak et al. (2020), in their evaluation of machine learning deployment across 21 clinical environments, highlight that involving clinicians in early co-design and system refinement improves alignment with clinical needs and strengthens trust in AI-generated recommendations. Implementation science further indicates that systems offering built-in training modules, in-service education, and rapid feedback loops achieve higher usability ratings and reduced alert fatigue, increasing adoption rates by approximately 20–40% in some quality improvement initiatives.

Despite these advances, most CDSS—particularly those incorporating advanced predictive analytics or explainable AI (XAI)—remain limited to pilot studies rather than routine clinical use. A meta-analysis reviewing 62 XAI-CDSS studies found that only 18 included clinical validation, usability testing, or real-world pilot deployment; the remainder were retrospective or offline analyses lacking workflow integration. This translational gap reflects persistent technical, organizational, and regulatory challenges. Regulatory uncertainty remains a major barrier. In many regions, AI-based CDSS are regulated as Software as a Medical Device (SaMD), requiring analytical validation, clinical performance evidence, and algorithm transparency before approval. Emerging regulations such as the EU AI Act further mandate post-market monitoring, risk assessment, and accountability for high-risk healthcare AI.

Additional barriers include interoperability limitations among EHR systems, inconsistent standards such as HL7 Fast Healthcare Interoperability Resources (FHIR), varying medical vocabularies (e.g., SNOMED, LOINC), and legacy systems that hinder real-time data exchange. Financial incentives are also limited, as reimbursement frameworks rarely reward CDSS adoption. In this context, explainable AI offers an important pathway toward regulatory compliance and clinical trust by providing transparent outputs that clinicians can interpret, evaluate, and responsibly incorporate into patient care decisions.



Figure. 4: *Chart illustrating the critical role of workflow integration in the successful deployment of AI-driven Clinical Decision Support Systems (CDSS).*

Figure. 4 explains why the technical performance will play second fiddle to the compatibility of the workflow to determine the real-world success. The chart puts emphasis on the Integration Premium, in which the implementation of tools in Electronic Health Records (EHR) leads to much higher adoption than discrete systems. Standalone interfaces as noted in the study pose a high cognitive load since clinicians have to alternate between screens and can be abandoned. In comparison, integrated systems provide recommendations at the point and time of care, which provides a much higher level of adoption (baseline of 30-60) to more than 60. The most successful implementations, with adoption rates of more than 90 percent, are those that involve integration of EHR and user-centred design and iterative feedback loops. This graphic information highlights the gap in the translation: many models are very accurate retrospectively, but do not work in practice without socio-technical alignment. The barriers of alert fatigue and technical silos can be overcome by means of applying such standards as HL7 FHIR to guarantee the interoperability and such a tool as Explainable AI to comply with the regulations of transparency. Finally, the analysis confirms that the CDSS needs to be a smooth continuation of the current workflow of the clinician, but not an external interference to be effective.

6. Synthesis and Implications for Practice

Altogether, the analysed evidence confirms that predictive analytics and explainable AI (XAI)-powered Clinical Decision Support Systems (CDSS) have significant potential to revolutionize the work with dementia, to improve its early diagnosis, risk evaluation, and treatment planning. These technologies have the ability to detect subtle patterns of thought and neuroimaging, predict the progression of the disease, and give practical answers that enable clinicians to make informed and timely decisions. But they only have clinical utility when they are optimized simultaneously with a number of other aspects that are dependent on each other. Predictive accuracy is not enough in it should be interpreted in a way that is understandable and transparent enough so that clinicians can understand and trust and take action on the model results. Another pillar is ethical governance which includes bias reduction, fairness, patient autonomy and compliance with regulations which protect equitable and socially responsible use. Adoption and sustained impact is also further determined by usability and integration in the actual clinical workflow. As stated consistently in the literature, this convergence is only possible with the help of a multidisciplinary team, including clinicians who know how to take care of patients, data scientists who create strong algorithms, ethicists who control the deployment of AI responsibly, and policymakers who build regulatory and reimbursement systems. This holistic, patient-centred methodology would see to it that the dementia CDSS are not only technologically advanced, but are also ethical, clinically viable, and consistent with the actualities of health care delivery. When applied together, predictive analytics and XAI can meet their goal of ensuring better results among people with dementia.

C. CONCLUSION

This study concludes that integrating predictive analytics with Explainable Artificial Intelligence (XAI) within Clinical Decision Support Systems (CDSS) represents a transformative advancement in dementia care. Predictive models consistently outperform conventional statistical approaches in detecting early cognitive decline, forecasting disease progression, and identifying individuals at high risk of developing Alzheimer's disease. These capabilities are crucial because timely intervention in dementia can delay functional deterioration, improve treatment planning, and enhance patients' quality of life. However, the findings clearly demonstrate that predictive accuracy alone is insufficient for real-world clinical implementation. The limited transparency, concerns about generalizability, and lack of clinician trust have hindered adoption. Therefore, explainability emerges not as an optional enhancement but as a fundamental requirement, enabling clinicians to interpret, validate, and responsibly apply AI-driven recommendations in high-stakes decision-making contexts.

The primary contribution of this paper lies in its integrative perspective, positioning predictive performance and explainability as complementary rather than competing objectives in dementia-focused CDSS. Conceptually, the study advances the discourse by emphasizing that clinical utility depends not only on algorithmic precision but also on interpretability, fairness, ethical alignment, and regulatory compliance. Practically, it highlights how XAI strengthens accountability, supports shared decision-making, clarifies medico-legal responsibility, and preserves professional autonomy by reinforcing CDSS as decision-support—not decision-replacement—tools. By synthesizing current evidence, this paper provides a structured framework for designing clinically trustworthy, ethically grounded, and implementation-ready AI systems in dementia management.

Despite promising developments, several limitations constrain the translation of dementia CDSS into routine practice. Many predictive models rely on demographically limited datasets, raising concerns about bias, equity, and generalizability across diverse populations. Furthermore, most studies employ retrospective validation with limited external or prospective clinical testing, potentially overstating real-world performance. The absence of standardized evaluation frameworks and long-term implementation studies further complicates comparison and adoption. Future research should prioritize large-scale, diverse, and longitudinal data collection; rigorous prospective validation; standardized evaluation metrics that include clinical utility and patient-centered outcomes; and the development of inherently interpretable models. Strengthening ethical governance, transparency standards, and interdisciplinary collaboration will be essential to ensure that AI-driven CDSS in dementia care are not only intelligent, but also fair, transparent, and socially responsible.

References

Arbabshirani, Mohammad R., Sergey Plis, Jing Sui, dan Vince D. Calhoun. 2017. "Single Subject Prediction of Brain Disorders in Neuroimaging: Promises and Pitfalls." *NeuroImage* 145:137–65. doi:10.1016/j.neuroimage.2016.02.079.

Bhandarkar, Anish, Pratham Naik, Kavita Vakkund, Srasthi Junjappanavar, Savita Bakare, dan Santosh Pattar. 2024. "Deep Learning Based Computer Aided Diagnosis of Alzheimer's Disease: A Snapshot of Last 5 Years, Gaps, and Future Directions." *Artificial Intelligence Review* 57(2):30. doi:10.1007/s10462-023-10644-8.

Choi, Edward, Mohammad Taha Bahadori, Jimeng Sun, Joshua Kulas, Andy Schuetz, dan Walter Stewart. 2016. "RETAIN: An Interpretable Predictive Model for Healthcare using Reverse Time Attention Mechanism." dalam *Advances in Neural Information Processing Systems*. Vol. 29. Curran Associates, Inc.

Clinical Decision Support (CDS) | Digital Healthcare Research. t.t. Diambil 10 Maret 2026. https://digital.ahrq.gov/health-it-tools-and-resources/clinical-decision-support-cds.

Holzinger, Andreas, Georg Langs, Helmut Denk, Kurt Zatloukal, dan Heimo Müller. 2019. "Causability and Explainability of Artificial Intelligence in Medicine." *WIREs Data Mining and Knowledge Discovery* 9(4):e1312. doi:10.1002/widm.1312.

International, Alzheimer's Disease. 2023. "World Alzheimer Report 2023: Reducing Dementia Risk: Never Too Early, Never Too Late." https://www.alzint.org/resource/world-alzheimer-report-2023/.

Jo, Taeho, Kwangsik Nho, dan Andrew J. Saykin. 2019. "Deep Learning in Alzheimer's Disease: Diagnostic Classification and Prognostic Prediction Using

Neuroimaging Data." *Frontiers in Aging Neuroscience* 11. doi:10.3389/fnagi.2019.00220.

Lundberg, Scott, dan Su-In Lee. 2017. "A Unified Approach to Interpreting Model Predictions."

Mehrabi, Ninareh, Fred Morstatter, Nripsuta Saxena, Kristina Lerman, dan Aram Galstyan. 2022. "A Survey on Bias and Fairness in Machine Learning." *ACM Computing Surveys* 54(6):1–35. doi:10.1145/3457607.

Mohsen, Saeed. 2025. "Alzheimer's Disease Detection Using Deep Learning and Machine Learning: A Review." *Artificial Intelligence Review* 58(9):262. doi:10.1007/s10462-025-11258-y.

Nguyen, Minh, Tong He, Lijun An, Daniel C. Alexander, Jiashi Feng, dan B. T. Thomas Yeo. 2020. "Predicting Alzheimer's Disease Progression Using Deep Recurrent Neural Networks." *NeuroImage* 222:117203. doi:10.1016/j.neuroimage.2020.117203.

Sendak, Mark P., William Ratliff, Dina Sarro, Elizabeth Alderton, Joseph Futoma, Michael Gao, Marshall Nichols, Mike Revoir, Faraz Yashar, Corinne Miller, Kelly Kester, Sahil Sandhu, Kristin Corey, Nathan Brajer, Christelle Tan, Anthony Lin, Tres Brown, Susan Engelbosch, Kevin Anstrom, Madeleine Clare Elish, Katherine Heller, Rebecca Donohoe, Jason Theiling, Eric Poon, Suresh Balu, Armando Bedoya, dan Cara O'Brien. 2020. "Real-World Integration of a Sepsis Deep Learning Technology Into Routine Clinical Care: Implementation Study." *JMIR Medical Informatics* 8(7):e15182. doi:10.2196/15182.

Sutton, Reed T., David Pincock, Daniel C. Baumgart, Daniel C. Sadowski, Richard N. Fedorak, dan Karen I. Kroeker. 2020. "An Overview of Clinical Decision Support Systems: Benefits, Risks, and Strategies for Success." *Npj Digital Medicine* 3(1):17. doi:10.1038/s41746-020-0221-y.

Tonekaboni, Sana, Shalmali Joshi, Melissa D. McCradden, dan Anna Goldenberg. 2019. "What Clinicians Want: Contextualizing Explainable Machine Learning for Clinical End Use."

UNESCO. 2021. "Recommendation on the Ethics of Artificial Intelligence."

Wang, Tingyan, Robin G. Qiu, dan Ming Yu. 2018. "Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks." *Scientific Reports* 8(1):9161. doi:10.1038/s41598-018-27337-w.

World Health Organization. 2023. "Dementia: Key Facts."